SEARCH:   Advanced

Blood, 23 April 2009, Vol. 113, No. 17, pp. 3947-3952. Prepublished online as a Blood First Edition Paper on November 5, 2008; DOI 10.1182/blood-2008-08-175778. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-08-175778v1 113/17/3947    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Adès, L. Articles by Fenaux, P. Search for Related Content PubMed PubMed Citation Articles by Adès, L. Articles by Fenaux, P. Related Collections Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study Lionel Adès1,2,11, Simone Boehrer1,2,11, Thomas Prebet3,11, Odile Beyne-Rauzy4,11, Laurence Legros5,11, Christophe Ravoet6,11, François Dreyfus7,11, Aspasia Stamatoullas8,11, Marie Pierre Chaury9,11, Jacques Delaunay10,11, Guy Laurent4,11, Norbert Vey3,11, Sara Burcheri1,11, Rose-Marie Mbida1,11, Natacha Hoarau1,11, Claude Gardin1,11, and Pierre Fenaux1,2,11 1 Hôpital Avicenne, Université Paris, Paris, France; 2 Inserm U848, Institut Gustave Roussy, Villejuif, France; 3 Institut Paoli Calmettes, Marseille, France; 4 Centre Hospitalo-Universitaire de Toulouse, Toulouse, France; 5 Centre Hospitalo-Universitaire Nice, Nice, France; 6 Hôpital de Jolimont, la Louviere, Belgium; 7 Hôpital Cochin, Université Paris, Paris, France; 8 Centre Hospitalo-Universitaire de Rouen, Rouen, France; 9 Centre Hospitalo-Universitaire de Limoges, Limoges, France; 10 Centre Hospitalo-Universitaire de Nantes, Nantes, France; and 11 Groupe Francophone des Myelodysplasies Higher-risk MDS with del5q carry a poor prognosis. In this phase 2 trial, 47 patients with higher-risk MDS received lenalidomide 10 mg/day. International Prognostic Scoring System was high in 60%, intermediate-2 risk in 40%. del 5q was isolated, with one additional and more than one additional abnormality in 19%, 23%, and 58% patients, respectively. Thirteen (27%) patients achieved hematologic response, including 7 hematologic complete remission (CR) (with complete [4] or partial [3] cytogenetic response), 2 marrow CR and 4 hematologic improvement erythroid, and 12 became red blood cell (RBC) transfusion independent, for a median duration of 6.5 months. Median CR duration was 11.5 months. Six of 9 (67%) patients with isolated del 5q achieved CR, versus 1 of 11 and none of 27 patients with one or more than one additional abnormality, respectively (P < .001). Seven of 20 (35%) with initial platelets more than 100 000/mm3 obtained CR, compared with none of the 27 with lower platelet counts less than 100 000/mm3 (P = .001). Our data support a potential role of lenalidomide in higher-risk MDS with isolated del 5q. This trial was registered at www.clinicaltrials.gov as NCT00424229 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: REVelation (del: 5q) Mikkael A. Sekeres Blood 2009 113: 3888-3889. [Full Text] [PDF] This article has been cited by other articles: M. A. Sekeres REVelation (del: 5q) Blood, April 23, 2009; 113(17): 3888 - 3889. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020